Serum lactate dehydrogenase levels in malignant germ cell tumors of ovary

1996 ◽  
Vol 6 (4) ◽  
pp. 328-332 ◽  
Author(s):  
P.S. Patel ◽  
V.M. Sharma ◽  
G.N. Raval ◽  
R.M. Rawal ◽  
M.M. Patel ◽  
...  
2001 ◽  
Vol 40 (4) ◽  
pp. 536-540 ◽  
Author(s):  
Finn Edler von Eyben ◽  
Ebbe Lindegaard Madsen ◽  
Ole Blaabjerg ◽  
Per Hyltoft Petersen ◽  
Hans von der Maase ◽  
...  

1983 ◽  
Vol 189 (2) ◽  
pp. 326-333 ◽  
Author(s):  
Finn E. von Eyben ◽  
Gunnar Skude ◽  
Sophie D. Fosså ◽  
Olbjørn Klepp ◽  
Ole Børmer

1993 ◽  
Vol 98 (3) ◽  
pp. 293-298 ◽  
Author(s):  
Finn Edler von Eyben ◽  
Per Hyltoft Petersen ◽  
Ole Blaabjerg ◽  
Ebbe Lindegaard Madsen ◽  
Bent Nørgaard-Pedersen ◽  
...  

2020 ◽  
Author(s):  
Kritika Krishnamurthy ◽  
Ana Maria Medina ◽  
Lydia Howard

Abstract Objective Because of its wide tissue distribution, elevation of serum lactate dehydrogenase (LD) is a nonspecific finding. Although serum LD is still included in the prognosis and staging of metastatic melanoma and germ cell tumors, its nonspecificity has led to decreased usefulness. Methods In this study, we analyzed the serum LD assays performed in a 726-bed hospital during a 1-year period and reviewed charts of patients with serum LD of >3 standard deviations (SD). Results Of 312 patients with elevated serum LD, only 9 were patients with melanoma and germ cell tumors. The other 303 patients had other malignancies, chronic conditions, and sepsis. Conclusion Elevated serum LD (even >3 SD) is an extremely nonspecific finding that does not contribute to clinical management in a majority of patients. As such, serum LD testing should be retired from routine clinical order sets and restricted in use.


Sign in / Sign up

Export Citation Format

Share Document